Voss, M. H., Hierro, C., Heist, R. S., Cleary, J. M., Meric-Bernstam, F., Tabernero, J., . . . Baselga, J. (2019). A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations. Clinical cancer research, 25(9), 2699. https://doi.org/10.1158/1078-0432.CCR-18-1959
Citácia podle Chicago (17th ed.)Voss, Martin H., et al. "A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations." Clinical Cancer Research 25, no. 9 (2019): 2699. https://doi.org/10.1158/1078-0432.CCR-18-1959.
Citácia podľa MLA (8th ed.)Voss, Martin H., et al. "A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations." Clinical Cancer Research, vol. 25, no. 9, 2019, p. 2699, https://doi.org/10.1158/1078-0432.CCR-18-1959.